Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Abstract

SAR439459 (SAR'459), a "second-generation" human anti-transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty-eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness-of-fit plots and adequately described the observed data by a two-compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment-emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.

Trial registration: ClinicalTrials.gov NCT03192345.

FIGURE 1

CONSORT diagram. AE, adverse event; CONSORT, Consolidated Standards of Reporting Trials; CRC, colorectal cancer; DLT, dose‐limiting toxicity; HCC, hepatocellular carcinoma; NSCLC, non‐small cell lung cancer; PD, progressive disease; QW, weekly; Q2W, every 2 weeks; Q3W, every 3 weeks; UC, urothelial cancer; W, withdrawal by subject.

FIGURE 2

Modulation of total TGFβ‐1 level by (a) SAR'459 monotherapy in plasma (Part 1) and (b) SAR'459 in combination with cemiplimab in plasma (Part 1); (c) low and high doses of SAR'459 monotherapy or in combination with cemiplimab in plasma (Part 2); (d) regulation of active TGFβ‐1 in tumor by SAR'459, alone and in combination with cemiplimab, in paired tumor biopsy samples (Part 2). C, cycle; CEM, cemiplimab; CRC, colorectal cancer; D, dose; EOT, end of treatment; HCC, hepatocellular carcinoma; NSCLC, non‐small cell lung cancer; Q3W, every 3 weeks; TGFβ, transforming growth factor beta, UC, urothelial cancer.